<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A02B&quot;,&quot;href&quot;:&quot;atc/A02B.md&quot;},{&quot;label&quot;:&quot;bismuth subcitrate&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;BismuthSubcitrate_Benet1991_reference&quot;,&quot;label&quot;:&quot;Benet_1991_reference&quot;,&quot;href&quot;:&quot;drugs/drug_bismuth_subcitrate/BismuthSubcitrate_Benet1991_reference.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;BismuthSubcitrate_Dresow1991_reference&quot;,&quot;label&quot;:&quot;Dresow_1991_reference&quot;,&quot;href&quot;:&quot;drugs/drug_bismuth_subcitrate/BismuthSubcitrate_Dresow1991_reference.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false}]"></div>

# bismuth subcitrate

- **generic name:** bismuth subcitrate
- **ATC codes:** `A02BX05`
- **DrugBank:** not captured · **PubChem:** not captured
- **groups:** not captured

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-18 04:10 | 1:48 | 0/2/0 | 0/1/0 | 0/0/0 | 32,814/1,965 | ollama / qwen3.8:27b-mtp-q8_0 | 5 | 2/3 | 5/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: no structural parameters extracted (nothing to build)</sub><br><sub>route_to: `human_review`</sub> | [Benet_1991_reference](drugs/drug_bismuth_subcitrate/BismuthSubcitrate_Benet1991_reference.md) | — | 1-compartment (no model) | 0 | Benet LZ, Safety and pharmacokinetics: colloidal…, Scandinavian journal of gas… (1991) | [10.3109/00365529109093217](https://doi.org/10.3109/00365529109093217) |
| <span class="pk-badge pk-badge--red">rejected</span><br><sub>blocking: no structural parameters extracted (nothing to build)</sub><br><sub>route_to: `human_review`</sub> | [Dresow_1991_reference](drugs/drug_bismuth_subcitrate/BismuthSubcitrate_Dresow1991_reference.md) | — | 1-compartment (no model) | 0 | Dresow B et al., Bioavailability of bismuth from 205Bi-l…, Archives of toxicology (1991) | [10.1007/BF02098030](https://doi.org/10.1007/BF02098030) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> | [Jin_2004_unknown](drugs/drug_bismuth_subcitrate/pd_Jin_2004_unknown.md) | enzyme activity ← bismuth subcitrate · inhibition effect | — | Jin L et al., Inhibition of alcohol dehydrogenase by…, Journal of inorganic bioche… (2004) | [10.1016/j.jinorgbio.2004.03.016](https://doi.org/10.1016/j.jinorgbio.2004.03.016) |

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 20 matched, 20 returned
- **screened:** 3  ·  **relevant:** 3
- **records:** 2  ·  extracted 0  ·  needs_review 0  ·  rejected 2  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_6 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Benet_1991.pdf` | Benet LZ, Safety and pharmacokinetics: colloidal…, Scandinavian journal of gas… (1991) | popPK | 9 | [10.3109/00365529109093217](https://doi.org/10.3109/00365529109093217) | [1957122](https://pubmed.ncbi.nlm.nih.gov/1957122) | The text explicitly reports quantitative pharmacokinetic parameters for bismuth subcitrate, including blood clearance (50-95 ml/min), bioavailability (0.16-0.28%), and half-life (5-11 days). |
| `Leussink_2000.pdf` | Leussink BT et al., Bismuth biokinetics and kidney histopat…, Archives of toxicology (2000) | popPK | 9 | [10.1007/s002040000150](https://doi.org/10.1007/s002040000150) | [11043489](https://pubmed.ncbi.nlm.nih.gov/11043489) | The study reports quantitative biokinetic parameters (absorption half-life, elimination half-life, peak concentration) for bismuth subcitrate in rats using a one-compartment model. |
| `Dresow_1991.pdf` | Dresow B et al., Bioavailability of bismuth from 205Bi-l…, Archives of toxicology (1991) | popPK | 8 | [10.1007/BF02098030](https://doi.org/10.1007/BF02098030) | [1747063](https://pubmed.ncbi.nlm.nih.gov/1747063) | The study reports quantitative PK parameters (half-lives, absorption percentages) for bismuth subcitrate in rats using a compartmental model. |
| `Beil_1993.pdf` | Beil W et al., Studies on the mechanism of action of c…, Pharmacology (1993) | pd | 4 | [10.1159/000139088](https://doi.org/10.1159/000139088) | [8395060](https://www.ncbi.nlm.nih.gov/pubmed/8395060) | metadata signals extractable PD data (IC50) |
| `Kuo_2009.pdf` | Kuo CH et al., Efficacy of levofloxacin-based rescue t…, The Journal of antimicrobia… (2009) | pgx | 5 | [10.1093/jac/dkp034](https://doi.org/10.1093/jac/dkp034) | [19246508](https://www.ncbi.nlm.nih.gov/pubmed/19246508) | metadata signals extractable PGX data (CYP2C19) |
| `Kuo_2013.pdf` | Kuo CH et al., Comparison of 10 day bismuth quadruple…, The Journal of antimicrobia… (2013) | pgx | 5 | [10.1093/jac/dks361](https://doi.org/10.1093/jac/dks361) | [22984204](https://www.ncbi.nlm.nih.gov/pubmed/22984204) | metadata signals extractable PGX data (CYP2C19) |

<sub>queue written 2026-09-18T04:08:51.848456+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Bakulina_2019 | not_relevant | 0 | 0 | The paper reports the effect of genetic polymorphisms on the clinical efficacy (eradication rate) of H. pylori therapy, not on the pharmacokinetic or pharmacodynamic parameters of bismuth subcitrate. |
| PGx | Kuo_2009 | not_relevant | 0 | 0 | The paper reports clinical efficacy and predictors of treatment failure (including CYP2C19 genotype) but does not report pharmacokinetic or pharmacodynamic parameters for bismuth subcitrate. |
| PGx | Kuo_2013 | not_relevant | 0 | 0 | The paper reports that CYP2C19 polymorphism did not influence the eradication effect (clinical outcome), but does not report any pharmacokinetic or pharmacodynamic parameters of bismuth subcitrate. |
| PD | Lee_1982 | not_relevant | 1 | 0 | The paper describes a qualitative mechanism of action (diffusion barrier) and qualitative tissue accumulation but provides no numeric concentration-effect or dose-response parameters. |
| PD | Li_2026 | not_relevant | 1 | 0 | The text is a mechanistic review describing molecular targets and qualitative therapeutic potential, lacking any quantitative exposure-response data, dose-effect curves, or numeric PD parameters. |
| PD | Nishimura_1993 | not_relevant | 1 | 0 | The study reports qualitative/percentage outcomes of a fixed-dose clinical trial without measuring drug concentrations or fitting a dose-response model to derive numeric PD parameters. |
| PD | Phillips_2000 | not_relevant | 3 | 2 | The paper reports in vitro MICs and in vivo eradication rates but does not provide a concentration-effect curve or numeric PD parameters (e.g., EC50, Emax) linking exposure to effect. |
| PGx | Veliev_2019 | not_relevant | 0 | 0 | The paper reports clinical efficacy and safety of H. pylori eradication regimens, not pharmacokinetic or pharmacodynamic parameters of bismuth subcitrate. |
| PGx | Wang_2022 | not_relevant | 0 | 0 | The paper investigates the effect of N-acetyl cysteine (NAC) on the pharmacokinetics of bismuth subcitrate, not the effect of a gene variant or genotype. |
| PD | Woo_2024 | not_relevant | 2 | 2 | The study reports Minimum Inhibitory Concentrations (MICs) and qualitative synergy results, but does not provide a concentration-effect curve, Emax/EC50 parameters, or a PK/PD model. |
| PGx | Wu_2011 | not_relevant | 0 | 0 | The paper compares two rescue therapies for H. pylori and mentions CYP2C19 genotyping, but it does not report any pharmacokinetic or pharmacodynamic parameters of bismuth subcitrate or how genetic variants affect them. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-18 04:08 UTC</sub>
